LENZ Therapeutics, Inc. (LENZ) Stock Forecast
LENZ analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.43 / 5 from 7 analysts
- Price target
- $23.86 average of analyst targets
- Upside to target
- +629.6% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.98
- 52-week range
- $3.27 – $36.31
LENZ analyst ratings
7 analystsNumber of analysts at each rating.
LENZ price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LENZ earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.95 | −$1.02 | −$0.85 | −$0.59 | −61.9% | 6 |
| Current fiscal year (2026) | −$4.20 | −$4.55 | −$3.83 | −$2.85 | −47.5% | 6 |
| Next fiscal year (2027) | −$2.91 | −$4.14 | −$2.35 | −$4.20 | +30.7% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LENZ revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.5M | $2.2M | $9.2M | −64.0% | 7 |
| Current fiscal year (2026) | $17.0M | $13.7M | $20.7M | −11.0% | 7 |
| Next fiscal year (2027) | $42.9M | $28.0M | $75.0M | +152.2% | 7 |
LENZ EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LENZ revenue: reported and forecast
LENZ EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.95 | −$0.98 | −$0.98 | −$0.98 | −$0.95 | +0.3% | 4 up · 3 down |
| Current fiscal year (2026) | −$4.57 | −$4.25 | −$4.25 | −$4.25 | −$4.20 | −8.0% | 4 up · 2 down |
| Next fiscal year (2027) | −$3.51 | −$3.08 | −$3.08 | −$3.08 | −$2.91 | −17.0% | 2 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LENZ earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LENZ beat in 6 of 12.
What analysts expect from LENZ
7 analysts cover LENZ Therapeutics; their consensus rating is buy (4.43 on a 1–5 scale, where 5 is a strong buy). The average price target is $23.86, 629.6% above the latest close of $3.27. Analysts expect earnings of −$4.20 per share for 2026, −47.5% from a year earlier. For 2027 the average estimate is −$2.91 per share on revenue of $42.9 million. LENZ Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: LENZ income statement, LENZ key metrics, LENZ chart. See the LENZ stock overview for the latest quote and news.
LENZ forecast FAQ
What is LENZ Therapeutics's price target?
The average analyst price target for LENZ Therapeutics is $23.86, 629.6% above the latest close of $3.27.
Is LENZ Therapeutics a buy, hold or sell?
Of 7 analysts covering LENZ Therapeutics, 5 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is LENZ Therapeutics's EPS forecast?
Analysts forecast −$4.20 per share for 2026 (range −$4.55 to −$3.83); for 2027 the estimate is −$2.91.
What is LENZ Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $17.0 million, growth of −11.0%; for 2027 it is $42.9 million.
When does LENZ Therapeutics report earnings?
LENZ Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.98.
Does LENZ Therapeutics usually beat earnings estimates?
LENZ Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.